日批在线视频_内射毛片内射国产夫妻_亚洲三级小视频_在线观看亚洲大片短视频_女性向h片资源在线观看_亚洲最大网

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Technology

Biotech breakthroughs showcase China's AI dominance

By Li Jing | chinadaily.com.cn | Updated: 2025-09-26 16:31
Share
Share - WeChat

China is emerging as one of the strongest drivers of artificial intelligence's shift from concept to clinical testing in the field of life sciences. From the discovery of novel drug candidates, to the delivery of advanced genetic therapies, enterprises have shown AI's potential in generating breakthroughs that may reshape the global pharmaceutical landscape.

This momentum was highlighted in the MIT Technology Review's 2025 "50 Smartest Companies" list, known as the TR50, released in September, where life sciences ranked among the top four sectors.

The Beijing-based biotech company, METiS TechBio, debuted on TR50 this year, reflecting the promise of its NanoForge platform, which uses AI to design lipid nanoparticles (LNPs) that can precisely carry RNA and gene-editing therapies to targeted organs.

The results are striking. METiS reported liver-targeting LNPs that exceeded existing clinical benchmarks and entered human trials. The company also tested lung-targeting systems that delivered mRNA into alveolar cells in primates, and first-in-class LNPs for heart and skeletal muscle tissue, which could enable new treatments for genetic cardiac disorders and muscular dystrophy.

"Delivery is the rocket of modern biotech. We're building the rockets that will carry tomorrow's therapeutic satellites," Chris Lai, co-founder and CEO of METiS TechBio, said, noting that rising investor confidence is fueling stronger collaboration between Chinese and global firms.

These advancements reflect the growth of China's innovation ecosystem. According to Stanford University's AI Index Report 2024, China accounted for 61.1 percent of global AI patent filings in 2022, far ahead of the United States at 20.9 percent. Analysts point to a decade of investment in AI talent, biomedical research, and supportive policy as the foundation for this new phase of growth.

Experts see this as part of a broader shift toward collaboration.

"With the rapid development of AI, we have seen an increasing number of pharmaceutical multinational corporations working with emerging biopharmaceutical companies in China in early drug development, as well as diagnosis and treatment", Wang Hongwei, professor at the School of Life Sciences and vice-president of Tsinghua University, told China Daily. "This kind of collaboration has already been formed as an innovative ecosystem in China."

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: 亚洲午夜久久久 | 国产18照片色桃 | 亚洲精品综合在线 | 久久不卡一区 | 亚洲国产成人久久 | 国产午夜精品一区二区三区嫩草 | 岛国精品在线观看 | 免费国产黄色 | 日少妇视频 | 岛国片在线免费观看 | 亚洲黄色免费看 | 欧美视频一区在线 | 日本精品久久久久 | 午夜欧美日韩 | 亚洲色女 | 国产精品av久久久久久无 | 韩国av中文字幕 | 亚洲激情一区二区三区 | 国产一区二区三区免费在线观看 | 91黄色大片 | 大片在线观看网站免费收看 | 日本久久99 | 成人欧美在线观看 | 欧美日韩三级 | 久久蜜臀av| 在线观看日本 | 1024久久| av精选| 日本成人综合 | 韩国一区二区三区视频 | 久久久国产一级片 | 中文字幕亚洲欧美日韩 | 国产亚洲精品精品精品 | 五月婷婷激情五月 | 视频一二三区 | 看一级黄色 | 中文字幕一区av | 国产麻豆成人传媒免费观看 | 日啪| 97毛片| 国产免费二区 |